Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway

Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway

Imatinib (IM), as first inhibitor of the oncogenic tyrosine kinase BCR-ABL, has been widely used to treat chronic myeloid leukemia (CML) for decades in clinic. However, resistance to IM usually occurs in CML patients. The bone marrow (BM), as the predominant microenvironment of CML, secretes an abun...

Full description

Bibliographic Details
Main Authors: Xiaobo Zhang, Yicheng Liu, Lu Lu, Shaoliang Huang, Youxiang Ding, Yi Zhang, Qinglong Guo, Zhiyu Li, Li Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-08-01
Series:Frontiers in Pharmacology
Subjects:
microenvironment
cell co-culture
drug resistance
hedgehog pathway
BCR-ABL
Oroxyloside A
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00526/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00526/full

Similar Items